pd 153035 has been researched along with Insulin Resistance in 1 studies
4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline: structure given in first source
PD-153035 : A member of the class of quinazolines carrying a 3-bromophenylamino substituent at position 4 and two methoxy substituents at positions 6 and 7.
Insulin Resistance: Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Prada, PO | 1 |
| Ropelle, ER | 1 |
| Mourão, RH | 1 |
| de Souza, CT | 1 |
| Pauli, JR | 1 |
| Cintra, DE | 1 |
| Schenka, A | 1 |
| Rocco, SA | 1 |
| Rittner, R | 1 |
| Franchini, KG | 1 |
| Vassallo, J | 1 |
| Velloso, LA | 1 |
| Carvalheira, JB | 1 |
| Saad, MJ | 1 |
1 other study available for pd 153035 and Insulin Resistance
| Article | Year |
|---|---|
EGFR tyrosine kinase inhibitor (PD153035) improves glucose tolerance and insulin action in high-fat diet-fed mice.
Topics: Adiponectin; Adipose Tissue; Animals; Blood Glucose; Dietary Fats; Enzyme Inhibitors; ErbB Receptors | 2009 |